{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Disease-modifying+anti-rheumatic+drugs&page=2", "query": { "intervention": "Disease-modifying anti-rheumatic drugs", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 72, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Disease-modifying+anti-rheumatic+drugs&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Disease-modifying+anti-rheumatic+drugs&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T22:27:35.606Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02451748", "title": "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Lab Work", "type": "OTHER" }, { "name": "Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)", "type": "DRUG" }, { "name": "Certolizumab pegol (CDP870, tradename Cimzia)", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Medrol", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "humira", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-08", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-10-11T22:27:35.606Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451748" }, { "nct_id": "NCT05413044", "title": "A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis", "Psoriatic Arthritis" ], "interventions": [], "intervention_types": [], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140706, "start_date": "2019-07-01", "completion_date": "2025-10-31", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-10-11T22:27:35.606Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05413044" }, { "nct_id": "NCT02047604", "title": "(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "SAN-300 0.5 mg/kg QW", "type": "DRUG" }, { "name": "SAN-300 1.0 mg/kg QW", "type": "DRUG" }, { "name": "SAN-300 2.0 mg/kg QOW", "type": "DRUG" }, { "name": "SAN-300 4.0 mg/kg QOW", "type": "DRUG" }, { "name": "SAN-300 4.0 mg/kg QW", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 41, "start_date": "2013-12", "completion_date": "2017-03-23", "has_results": true, "last_update_posted_date": "2021-06-21", "last_synced_at": "2026-10-11T22:27:35.606Z", "location_count": 12, "location_summary": "Phoenix, Arizona • El Cajon, California • Los Angeles, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "El Cajon", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Leandro", "state": "California" }, { "city": "Brandon", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02047604" }, { "nct_id": "NCT02584855", "title": "A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 394, "start_date": "2015-09-14", "completion_date": "2018-10-30", "has_results": true, "last_update_posted_date": "2019-11-15", "last_synced_at": "2026-10-11T22:27:35.606Z", "location_count": 22, "location_summary": "Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 19 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Leandro", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584855" }, { "nct_id": "NCT05421442", "title": "A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis (RA)", "Psoriatic Arthritis (PsA)" ], "interventions": [], "intervention_types": [], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38396, "start_date": "2019-06-13", "completion_date": "2025-10-31", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-10-11T22:27:35.606Z", "location_count": 1, "location_summary": "Lawrenceville, New Jersey", "locations": [ { "city": "Lawrenceville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05421442" }, { "nct_id": "NCT00902486", "title": "INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "INCB028050", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2009-05", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2018-09-04", "last_synced_at": "2026-10-11T22:27:35.606Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00902486" }, { "nct_id": "NCT03970837", "title": "Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "GSK3196165 (Otilimab)", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1764, "start_date": "2019-06-05", "completion_date": "2023-01-18", "has_results": true, "last_update_posted_date": "2023-11-30", "last_synced_at": "2026-10-11T22:27:35.606Z", "location_count": 64, "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03970837" }, { "nct_id": "NCT01844518", "title": "Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Active Polyarticular Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 219, "start_date": "2013-08-30", "completion_date": "2023-02-01", "has_results": true, "last_update_posted_date": "2023-07-12", "last_synced_at": "2026-10-11T22:27:35.606Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844518" }, { "nct_id": "NCT01307423", "title": "Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Apremilast 20mg", "type": "DRUG" }, { "name": "Apremilast 30mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 529, "start_date": "2010-12-09", "completion_date": "2017-08-16", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-11T22:27:35.606Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01307423" }, { "nct_id": "NCT01232569", "title": "A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tocilizumab 162 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 656, "start_date": "2011-03", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-07-29", "last_synced_at": "2026-10-11T22:27:35.606Z", "location_count": 44, "location_summary": "Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 36 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01232569" } ] }